FLAURA2 Trial: Osimertinib Effectively Combats NSCLC

The phase 3 FLAURA2 trial evaluated osimertinib with or without chemotherapy in first‑line advanced EGFR‑mutated NSCLC. In the randomized study, 557 patients with exon 19 deletion or L858R EGFR mutations received either osimertinib monotherapy or osimertinib plus platinum-pemetrexed chemotherapy.

Trial findings demonstrated that the latter arm resulted in “significantly longer” progression-free survival than osimertinib monotherapy, according to the study authors, with a median progression-free survival of 25.5 months versus 16.7 months in patients treated with monotherapy. Osimertinib plus chemotherapy also resulted in a response rate of 83% compared to 76% in the other arm.

Read the full study published in the New England Journal of Medicine.

Learn more about the importance of osimertinib data from the FLAURA2 and LAURA trials.